Krystal Biotech, Inc. KRYS
Krystal Biotech, Inc. (Nasdaq: KRYS) is a rare genetic drug developer. Its lead program, VYJUVEK (beremagene geperpavec-svdt, B-VEC), is in Phase 3 for Dystrophic epidermolysis bullosa. Its next catalyst on record is KB803: IOLITE Phase 3 top-line results (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KB803 — IOLITE Phase 3 top-line results (2026). 10 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VYJUVEK (B-VEC) | Dystrophic epidermolysis bullosa (approved US, EU, UK, Japan) | gene therapy | Approved |
| KB803 | Corneal abrasions in DEB (IOLITE Phase 3 registrational) | gene therapy | Phase 3 |
| KB801 | Neurotrophic keratitis (EMERALD-1, registrational, placebo-controlled) | gene therapy | Phase 2 |
| KB707 (inhaled and intratumoral) | NSCLC; Gorlin syndrome / basal cell carcinoma | gene therapy | Phase 2 |
| KB407 | Cystic fibrosis | gene therapy | Phase 1 |
| KB111 | Hailey-Hailey disease | gene therapy | Phase 1 |
| KB408 | Alpha-1 antitrypsin deficiency lung disease | gene therapy | Phase 1 |
| KB304 (Jeune Aesthetics) | Wrinkles of the decollete | gene therapy | Phase 1 |
Recent results and decisions
- Aug 3, 2026positive Interim KYANITE-1 dose-expansion data (ASCO, May 2026): ORR 31%, disease control rate 75%, duration of response and PFS not reached.
achieving an objective response rate (ORR) of 31% and a disease control rate of 75%
Filing - Nov 3, 2025approval Updated US VYJUVEK label expands the eligible patient population and adds patient flexibility (details not in the supplied text; reported as a recent event).
Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.